GlassScriptPhysician profile
Deborah Ann Fore
NPI 1962286344
$1,095.88
in general payments reported to CMS, 2019-2025
15 companies · $972 in 2025
The $972 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $14.89 · 2024: $109 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.89 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.63 | 2024-2025 | |
| Janssen Biotech, INC. | $213.86 | 2025 | Tremfya |
| Aimmune Therapeutics, INC. | $92.91 | 2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $92.71 | 2025 | Eohilia, Entyvio |
| Ardelyx, INC. | $71.68 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.82 | 2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $33.63 | 2025 | Dupixent |
| Novo Nordisk INC | $31.87 | 2023-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $24.93 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $24.22 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $19.55 | 2024 | Breztri |
| Gilead Sciences, INC. | $17.45 | 2025 | |
| Lilly USA, LLC | $16.70 | 2024 | Mounjaro |
| Exact Sciences Corporation | $16.37 | 2024 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $14.55 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Fore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.